(Q34425234)

2 August 2017

title

Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer (English)

1 reference

2 August 2017

1 reference

Lin-Run Wang

1

1 reference

2 August 2017

Ming-Zhu Huang

2

1 reference

2 August 2017

Nong Xu

3

1 reference

2 August 2017

Jian-Zhong Shentu

4

1 reference

2 August 2017

Jian Liu

5

1 reference

2 August 2017

Jie Cai

6

1 reference

2 August 2017

language of work or name

1 reference

1 May 2005

1 reference

Journal of Zhejiang University. Science. B

2 August 2017

published in

1 reference

2 August 2017

volume

6

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

446-450

1 reference

Preclinical, pharmacologic, and phase I studies of gemcitabine

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Gemcitabine safety overview.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Clinical, toxicological and pharmacological aspects of gemcitabine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1389765

Action of 2',2'-difluorodeoxycytidine on DNA synthesis

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15822162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15822162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15822162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1631/JZUS.2005.B0446

1 reference

2 August 2017

1 reference

2 August 2017

1 reference